🇺🇸 fosnetupitant/ palonosetron in United States

32 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Death — 11 reports (34.38%)
  2. Dyspnoea — 4 reports (12.5%)
  3. Cough — 3 reports (9.38%)
  4. Back Pain — 2 reports (6.25%)
  5. Cold Sweat — 2 reports (6.25%)
  6. Disease Progression — 2 reports (6.25%)
  7. Fatigue — 2 reports (6.25%)
  8. Flushing — 2 reports (6.25%)
  9. Nausea — 2 reports (6.25%)
  10. Off Label Use — 2 reports (6.25%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is fosnetupitant/ palonosetron approved in United States?

fosnetupitant/ palonosetron does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for fosnetupitant/ palonosetron in United States?

Helsinn Healthcare SA is the originator. The local marketing authorisation holder may differ — check the official source linked above.